中文  |  ENGLISH

科研团队

当前位置:首页 > PI


储剑虹

教授,博士生导师

 

江苏省苏州市工业园区仁爱路199
苏州大学造血干细胞移植研究所
电话:
传真:

E-mail: jhchu@suda.edu.cn

 

教育背景:

1997年-2002年  安徽医科大学   临床医学           学士
2002
-2005年  复旦大学      药理学             硕士

2005年-2008年  香港中文大学  解剖学             博士

2009年-2012年  香港浸会大学中医药学院           博士后

2012年-2015年  美国俄亥俄州立大学内科血液学部门 博士后

 

工作经历:

2015年10-至今 苏州大学造血干细胞移植研究所  特聘教授

 

研究方向:

1. 恶性肿瘤靶向免疫治疗的基础研究与临床应用

2. 自然杀伤细胞的成熟、发育与效应功能的分子调控机制

 

团队成员:

技术员:朱婷婷,硕士,
硕士研究生:蒋东鹏、张瑞茜,

代表性成果:

*通讯作者,#共同一作)

1.      Zhao S, Zhang L, Han J, Chu J, et al. Conformal Nanoencapsulation of Allogeneic T Cells Mitigates Graft-Versus-Host Disease and Retains Graft-Versus-Leukemia Activity. ACS Nano. 2016 May 25.

2.      Chen X#, Han J#, Chu J#, et al. A Combinational Therapy of EGFR-CAR NK Cells and Oncolytic Herpes Simplex Virus 1 for Breast Cancer Brain Metastases. Oncotarget. 2016 Apr 1. doi: 10.18632/oncotarget.8526.

3.      Cao H#, Chu J#, Kwan H#, Tao S, et al. Inhibition of the Stat3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma. Scientific Reports. 2016 Feb 25;6:21731.

4.      Zhang L, Chu J, Yu J, Wei W. Cellular and molecular mechanisms in graft-versus-host disease. J Leukoc Biol. 2016 Feb;99(2):279-87.

5.      Han J, Chen X, Chu J, Xu B, et al. TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response. Cancer Research. 2015;75(24):5273-82.

6.      Han J#, Chu J#, Zhang J, et al. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. Scientific Reports. 2015; 5:11483.

7.      Deng Y#, Kerdiles Y#, Chu J#, et al. Transcription factor Foxo1 is a Negative Regulator of Natural killer Cell Maturation and Function. Immunity. 2015; 42(17):457-470.

8.      Chu J#, Deng Y#, Benson D, et al. CS1-Specific Chimeric Antigen Receptor (CAR)-Engineered Natural Killer Cells Enhance In Vitro and In Vivo Anti-tumor Activity Against Human Multiple Myeloma. Leukemia. 2014; 28(4):917-27.

9.      Chu J#, He S#, Deng Y#, et al. Genetic Modification of T cells Redirected towards CS1 Enhances Anti-Myeloma activity. Clinical Cancer Research. 2014;20(15): 3989-4000. Comment in Clinical Cancer Res. 2014; 20(15):3899-3901.

10.   Deng Y#, Chu J#, Ren Y#, et al. The Natural Product Phyllanthusmin C Enhances IFN-γ Production by Human Natural Killer Cells through Upregulation of TLR-mediated NF-kappaB Signaling. Journal of Immunology. 2014;193(6):2994-3002.

11.   He S, Chu J, Deng YC, et al. FLT3L and Plerixafor Combination Increases Hematopoietic Stem Cell Mobilization and Leads to Improved Transplantation Outcome. Biology of Blood and Marrow Transplantation. 2014; 20(3):309-13.

12.   He S, Chu J, Wu L, et al. MicroRNAs Activate Natural Killer Cells through Toll-like Receptor Signaling. Blood. 2013;121(23):4663-71.

13.   Du W, Wang S, Zhou Q, Li X, Chu J, et al. ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer. Oncogene. 2013; 32(28):3319-28.

14.   Chung K, Cheng I, Ching A, Chu J, et al. Block of proliferation 1 (BOP1) plays an oncogenic role in hepatocellular carcinoma by promoting epithelial-to-mesenchymal transition. Hepatology. 2011; 54(1):307-18.

15.   Li Y, Zhu G, Shen L, Chu J, et al. Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells. Cancer Chemother Pharmacol. 2011; 68(5):1315-23.

16.    Li Y, Zhu G, Shen X, Chu J, et al. Furanodienone Inhibits Estrogen Receptor Alpha Dependent Breast Cancer MCF-7 Cells Proliferation. J Cell Biochem. 2011;112(1):217-24.

17.   Chu J, Wang H, Ye Y, et al. Anti-steatosis effects and mechanisms of schisandrin B in free fatty acids-induced steatotic L-02 cells. World J Gastroenterol. 2011; 17(19):2379-88.

18.   Chu J, Yu S, Hayward S, Chan FL. Development of a three-dimensional culture model of prostatic epithelial cells and its use for the study of epithelial-mesenchymal transition and inhibition of PI-3K pathway in prostate cancer. The Prostate, 2009, 69:428-442.

 

专利发明:

Jianhua Yu, Hofmeister Craig and Jianhong Chu. CS1-specific Chimeric Antigen Receptor (CAR) Engineered Immune Cells. PCT国际专利(编号: PCT/US2014/036684. WO2014/179759)